<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="145427">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01207440</url>
  </required_header>
  <id_info>
    <org_study_id>AP24534-10-201</org_study_id>
    <secondary_id>2010-020414-28</secondary_id>
    <nct_id>NCT01207440</nct_id>
  </id_info>
  <brief_title>Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph+ Acute Lymphoblastic Leukemia (ALL)</brief_title>
  <acronym>PACE</acronym>
  <official_title>A Pivotal Phase 2 Trial of Ponatinib (AP24534) in Patients With Refractory Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ariad Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ariad Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the efficacy of ponatinib in patients with chronic
      myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or
      with Ph positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or
      intolerant to either dasatinib or nilotinib, or have the T315I mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The preliminary analysis of the phase 1 clinical trial revealed evidence of clinical
      antitumor activity in patients with resistance to approved second-generation tyrosine kinase
      inhibitors (TKI), dasatinib and nilotinib, including patients with the T315I mutation of the
      BCR-ABL gene (BCR-ABL). This Phase 1 study, taken together with the strong preclinical data
      that characterize ponatinib, provides the rationale for moving to a pivotal phase 2 trial of
      this agent in a population of patients with chronic myeloid leukemia (CML) and Ph+ Acute
      Lymphoblastic Leukemia (ALL) who are resistant or intolerant to prior TKI therapy and in
      those patients with the T315I mutation.

      PACE is a multi-center, international, phase 2, uncontrolled, open-label trial of oral
      ponatinib in patients with Philadelphia chromosome-positive (Ph+) disease.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major cytogenetic response (MCyR) in CP-CML patients</measure>
    <time_frame>up to 48 months after first dose</time_frame>
    <description>Defined as complete cytogenetic response (CCyR) or partial cytogenetic response (PCyR).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major hematologic response (MaHR) in AP-CML patients</measure>
    <time_frame>up to 48 months after first dose</time_frame>
    <description>Consists of complete hematologic response (CHR) or no evidence of leukemia (NEL)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>MaHR in BP-CML/Ph+ALL patients</measure>
    <time_frame>up to 48 months after first dose</time_frame>
    <description>Consists of CHR or NEL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responses in CP-CML patients</measure>
    <time_frame>up to 48 months after first dose</time_frame>
    <description>The composite of:
Hematologic responses: CHR;
Cytogenetic responses: confirmed MCyR; and
Molecular response: major molecular response (MMR).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responses in AP-CML or BP-CML/Ph+ ALL patients</measure>
    <time_frame>up to 48 months after first dose</time_frame>
    <description>The composite of:
Cytogenetic responses: CCyR, PCyR, confirmed MCyR; and
Molecular response: MMR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Responses in all patients</measure>
    <time_frame>up to 48 months after first dose</time_frame>
    <description>The composite of time to response, duration of response, progression free survival, and overall survival.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and tolerability for all patients</measure>
    <time_frame>up to 48 months after first dose</time_frame>
    <description>The Adverse Event (AE) incidence rates as well as the frequency of occurrence of overall toxicity, categorized by toxicity grades (severity) will be described for each cohort of the trial. Listings of laboratory test results will also be generated, and descriptive statistics summarizing the changes in laboratory tests over time will be presented.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">449</enrollment>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Ph+ Acute Lymphoblastic Leukemia</condition>
  <arm_group>
    <arm_group_label>CP-CML R/I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Chronic Phase (CP) CML resistant or intolerant (R/I) to dasatinib or nilotinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AP-CML R/I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Accelerated Phase (AP) CML resistant or intolerant (R/I) to dasatinib or nilotinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Blast Phase (BP) CML / Ph+ ALL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blast Phase (BP) CML or Ph+ ALL resistant or intolerant (R/I) to dasatinib or nilotinib or Ph+ ALL resistant or intolerant (R/I) to dasatinib or nilotinib</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CP-CML with T315I mutation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CP-CML patients who have the T315I mutation of BCR-ABL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AP-CML with T315I mutation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>AP-CML patients who have the T315I mutation of BCR-ABL</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BP-CML / Ph+ ALL with T315I mutation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BP-CML or Ph+ ALL patients who have the T315I mutation of BCR-ABL</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ponatinib</intervention_name>
    <description>45 mg dose taken orally once daily</description>
    <arm_group_label>CP-CML R/I</arm_group_label>
    <arm_group_label>AP-CML R/I</arm_group_label>
    <arm_group_label>Blast Phase (BP) CML / Ph+ ALL</arm_group_label>
    <arm_group_label>CP-CML with T315I mutation</arm_group_label>
    <arm_group_label>AP-CML with T315I mutation</arm_group_label>
    <arm_group_label>BP-CML / Ph+ ALL with T315I mutation</arm_group_label>
    <other_name>AP24534</other_name>
    <other_name>Iclusig</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have CML in any phase (CP, AP, or BP of any phenotype) or Ph+ ALL

          -  Previously treated with and developed resistance or intolerance to dasatinib or
             nilotinib OR developed the T3151 mutation after any tyrosine kinase inhibitor (TKI)
             therapy

          -  ≥18 years old

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Minimum life expectancy of ≥3 months

          -  Adequate kidney function

          -  Adequate liver function

          -  Normal pancreatic function

          -  Normal QT Fridericia-corrected interval (QTcF) ≤450 ms for males and ≤470 ms for
             females

          -  Negative pregnancy test (if woman of childbearing potential)

          -  Agree to use effective form of contraception (as applicable)

          -  Ability to comply with study procedures, in the Investigator's opinion

        Exclusion Criteria:

          -  Received prior TKI treatment within 7 days prior to receiving the first dose of
             ponatinib, or have not recovered from adverse events (except alopecia) due to agents
             previously administered.

          -  Received other therapies as follows:

               1. For CML chronic phase (CP) and accelerated phase (AP) patients, received
                  hydroxyurea or anagrelide within 24 hours prior to receiving the first dose of
                  ponatinib; interferon, cytarabine, or immunotherapy within 14 days prior to
                  first dose of ponatinib; or any other cytotoxic chemotherapy, radiotherapy, or
                  investigational therapy within 28 days prior to receiving the first dose of
                  ponatinib.

               2. For CML blast phase (BP) patients, received chemotherapy within 14 days prior to
                  the first dose of ponatinib.

               3. For Ph+ ALL patients, received corticosteroids within 24 hours before the first
                  dose of ponatinib; or vincristine within 7 days prior to the first dose of
                  ponatinib; or received other chemotherapy within 14 days prior to the first dose
                  of ponatinib.

          -  Underwent stem cell transplant &lt;60 days prior to receiving first dose of ponatinib

          -  Evidence of on-going graft versus-host disease (GVHD), or GVHD requiring
             immunosuppressive therapy

          -  Taking medications that are known to be associated with Torsades de Pointes

          -  Require concurrent treatment with immunosuppressive agents (other than
             corticosteroids prescribed for a short course of therapy)

          -  Previously treated with ponatinib

          -  CML CP patients are excluded if they are in Complete cytogenetic response (CCyR)

          -  Patients with CML AP, CML BP, or Ph+ ALL are excluded if they are in Major
             Hematologic Response (MaHR).

          -  Have active Central Nervous System (CNS) disease

          -  Have significant or active cardiovascular disease

          -  Have a significant bleeding disorder unrelated to CML or Ph+ALL

          -  Have a history of pancreatitis or alcohol abuse

          -  Have uncontrolled hypertriglyceridemia (triglycerides &gt;450 mg/dL)

          -  Have malabsorption syndrome or other gastrointestinal illness that could affect
             absorption of ponatinib

          -  Diagnosed with another primary malignancy in the past 3 years

          -  Pregnant or lactating

          -  Underwent major surgery within 14 days prior to first dose of ponatinib

          -  Have ongoing or active infection

          -  Suffer from any other condition or illness that would compromise safety or interfere
             with evaluation of the drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA Ronald Reagan Medical Center, Site #027</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>H. Lee Moffitt Cancer Center &amp; Research Institute, Site #017</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Winship Cancer Institute, Site # 058</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine, Site # 023</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Chicago, Site # 001</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland, Greenebaum Cancer Center, Site # 040</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute , Site # 008</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Medical Center, Site # 011</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute, Site # 034</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, Site # 007</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110-1093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nebraska Hematology-Oncology, PC, Site #133</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northern New Jersey Cancer Associates, Site #128</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute, Site #029</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health and Sciences University, Site #048</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center, Site # 005</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute at the University of Utah, Site #043</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center, Site #100</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital, Site #941</name>
      <address>
        <city>St. Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital, Site #942</name>
      <address>
        <city>Woollongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital, Site #951</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000a</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter MacCallum Cancer Center, Site #950</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires St-Luc, Site #508</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven Campus Gasthuisberg, Site #700</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gordon &amp; Leslie Diamond Health Care Centre, Site #130</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa General Hospital, Site #131</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network, Princess Margaret Hospital, Site # 083</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McGill University Department of Oncology, Site # 132</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2S 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital, Site #129</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Archet I, Site #509</name>
      <address>
        <city>Nice</city>
        <state>Cedex 03</state>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Saint-Louis, Site #957</name>
      <address>
        <city>Paris</city>
        <state>Cedex 10</state>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie, Site 772</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen, Site #953</name>
      <address>
        <city>Cedex</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Edouard Herriot, Site #956</name>
      <address>
        <city>Cedex</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CH de Versailles, Site #958</name>
      <address>
        <city>Le Chesnay Cedex</city>
        <zip>78 157</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Claude Huriez CHRU de Lille, Site #952</name>
      <address>
        <city>Lille cedex</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers, Site #954</name>
      <address>
        <city>Poitiers cedex</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Purpan, Site #955</name>
      <address>
        <city>Toulouse</city>
        <zip>30059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite - Universitatsmedizin Berlin, Site #701</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Jena, Site #946</name>
      <address>
        <city>Jena</city>
        <zip>07747</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Fakultat Mannheim der Universitat Heidelberg, Site #947</name>
      <address>
        <city>Mannheim</city>
        <zip>68169</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>III. Med. Klinik und Poliklini, Site #949</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto di Ematologia &quot;L. &amp; A. Seragnoli, Site # 959</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Gerardo Hospital, Site #961</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SCDU Medicina Interna II - Indirizzo, Site #785</name>
      <address>
        <city>Orbassano</city>
        <zip>10043</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>U.O. di Ematologia - Ospedale S. Eugenio, Site #962</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Site #938</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VU University Medical Center, Site #948</name>
      <address>
        <city>Amsterdam,</city>
        <zip>1081 HV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center Groningen, Site #507</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Singapore General Hospital, Site #939</name>
      <address>
        <city>Blk 6 Level 5</city>
        <zip>169608</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic, Site #963</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz, Site #966</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca, Site #965</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia, Site #964</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital, Site #944</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital, Site #945</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Glasgow, Site #797</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0XB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Liverpool and Broadgreen University Hospitals NHG Trust, Site #969</name>
      <address>
        <city>Liverpool</city>
        <zip>L7 8XP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust, Hammersmith Hospital, Site #967</name>
      <address>
        <city>London</city>
        <zip>W12 0NN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle University Medical School, Site #970</name>
      <address>
        <city>Newcastle-upon-Tyne</city>
        <zip>NE2 4HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham University Hospitals Trust, Site #968</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nejm.org/doi/full/10.1056/NEJMoa1306494</url>
    <description>Cortes et al. A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias. N Engl J Med 2013; 369:1783-1796</description>
  </link>
  <verification_date>March 2016</verification_date>
  <lastchanged_date>October 28, 2016</lastchanged_date>
  <firstreceived_date>September 20, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CML</keyword>
  <keyword>ALL</keyword>
  <keyword>PH</keyword>
  <keyword>ponatinib</keyword>
  <keyword>Ph+ALL</keyword>
  <keyword>T315I mutation</keyword>
  <keyword>Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ponatinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
